Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project

Abstract Clinical pharmacogenomics (PGx) has the potential to make pharmacotherapy safer and more effective by utilizing genetic patient data for drug dosing and selection. However, widespread adoption of PGx depends on its successful integration into routine clinical care through clinical decision support tools, which is often hampered by insufficient or fragmented infrastructures. This paper describes the setup and implementation of a unique multimodal, multilingual clinical decision support intervention consisting of digital, paper-, and mobile-based tools that are deployed across implementation sites in seven European countries participating in the Ubiquitous PGx (U-PGx) project.

[1]  Ching-Hon Pui,et al.  PG4KDS: A model for the clinical implementation of pre‐emptive pharmacogenetics , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[2]  Christian Nøhr,et al.  International health IT benchmarking: learning from cross-country comparisons , 2016, J. Am. Medical Informatics Assoc..

[3]  Diane Hauser,et al.  The IGNITE network: a model for genomic medicine implementation and research , 2015, BMC Medical Genomics.

[4]  Christopher G Chute,et al.  Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. , 2014, Mayo Clinic proceedings.

[5]  Julie A Johnson,et al.  Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. , 2013, Pharmacogenomics.

[6]  Henk-Jan Guchelaar,et al.  Translating Pharmacogenomics: Challenges on the Road to the Clinic , 2007, PLoS medicine.

[7]  M. Relling,et al.  Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group , 2018, Clinical pharmacology and therapeutics.

[8]  Munir Pirmohamed,et al.  A Randomized Trial of Genotype-Guided Dosing of Warfarin , 2014 .

[9]  Henk-Jan Guchelaar,et al.  Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients. , 2016, Pharmacogenomics.

[10]  Xiang Zhou,et al.  Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai. , 2017, Pharmacogenomics.

[11]  Tracy H. Porter,et al.  Seven years after Meaningful Use: Physicians’ and nurses’ experiences with electronic health records , 2017, Health care management review.

[12]  Michelle Whirl-Carrillo,et al.  Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC) , 2016, Genetics in Medicine.

[13]  Roy Fielding,et al.  Architectural Styles and the Design of Network-based Software Architectures"; Doctoral dissertation , 2000 .

[14]  Patrick Kierkegaard,et al.  Interoperability after deployment: persistent challenges and regional strategies in Denmark. , 2015, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[15]  Henk-Jan Guchelaar,et al.  Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. , 2016, European journal of cancer.

[16]  M. Relling,et al.  Development and use of active clinical decision support for preemptive pharmacogenomics , 2013, Journal of the American Medical Informatics Association : JAMIA.

[17]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[18]  F. Mostashari Office of the National Coordinator for Health Information Technology Attention: Governance RFI , 2005 .

[19]  Soma Das,et al.  Adoption of a clinical pharmacogenomics implementation program during outpatient care–initial results of the University of Chicago “1,200 Patients Project” , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[20]  N J Cox,et al.  The 1200 Patients Project: Creating a New Medical Model System for Clinical Implementation of Pharmacogenomics , 2012, Clinical pharmacology and therapeutics.

[21]  Kevin B. Johnson,et al.  Electronic health record design and implementation for pharmacogenomics: a local perspective , 2013, Genetics in Medicine.

[22]  Stijn Heymans,et al.  Semantic validation of the use of SNOMED CT in HL7 clinical documents , 2011, J. Biomed. Semant..

[23]  Rita Barallon,et al.  A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. , 2013, The New England journal of medicine.

[24]  E. Balas,et al.  Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success , 2005, BMJ : British Medical Journal.

[25]  Aniwaa Owusu Obeng,et al.  Clinical pharmacogenetics implementation: Approaches, successes, and challenges , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[26]  Megan Doerr,et al.  Cleveland Clinic's Center for personalized healthcare: setting the stage for value-based care. , 2014, Pharmacogenomics.

[27]  Gianrico Farrugia,et al.  Multidisciplinary Model to Implement Pharmacogenomics at the Point of Care , 2016, Genetics in Medicine.

[28]  Matthias Samwald,et al.  Examining perceptions of the usefulness and usability of a mobile-based system for pharmacogenomics clinical decision support: a mixed methods study , 2016, PeerJ.

[29]  M O Karlsson,et al.  Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium , 2017, Clinical pharmacology and therapeutics.

[30]  E. Clayton,et al.  Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project , 2012, Clinical pharmacology and therapeutics.

[31]  Charis Eng,et al.  Implementation of Clinical Pharmacogenomics within a Large Health System: From Electronic Health Record Decision Support to Consultation Services , 2016, Pharmacotherapy.

[32]  Matthias Samwald,et al.  Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available , 2016, PloS one.

[33]  Jeffrey C. Hall,et al.  The CLIPMERGE PGx Program: Clinical Implementation of Personalized Medicine Through Electronic Health Records and Genomics–Pharmacogenomics , 2013, Clinical pharmacology and therapeutics.

[34]  Patrick Kierkegaard,et al.  eHealth in Denmark: A Case Study , 2013, Journal of Medical Systems.

[35]  Sowmya R. Rao,et al.  Use of electronic health records in U.S. hospitals. , 2009, The New England journal of medicine.

[36]  Melissa Rawley-Payne,et al.  University of Florida Clinical and Translational Science Institute: Transformation and Translation in Personalized Medicine , 2011, Clinical and translational science.

[37]  Henk-Jan Guchelaar,et al.  Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. , 2015, Gastroenterology.

[38]  Keith Marsolo,et al.  Practical considerations in genomic decision support: The eMERGE experience , 2015, Journal of pathology informatics.